75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss 2
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Consolidated Statements of Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Condensed Consolidated Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization and Nature of the Business
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Cash, Cash Equivalents and Restricted Cash
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Other Accrued Expenses
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Licensing Activities and Business Development
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Long-Term Debt
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Other Accrued Expenses (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Long-Term Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Organization and Nature of the Business - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Other Accrued Expenses - Summary of Other Accrued Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Licensing Activities and Business Development - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Long-Term Debt - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Long-Term Debt - Summary of Obligations Under the Term Loan Facility (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Long-Term Debt - Scheduled Annual Principal Payments for Term Loan (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Stockholders' Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Net Loss Per Share - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Segment Information - Schedule of Significant Segment Expense Categories (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Segment Information - Schedule of Significant Segment Expense Categories (Parentheticals) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
AbbVie Deutschland GmbH & Co. KG
AbbVie Deutschland GmbH & Co. KG [Member]
AbbVie [Member]
Segments [Domain]
Development and Regulatory [Member]
Development and regulatory.
Development and Regulatory [Member]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued, Total
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred stock issued
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]
Increase (Decrease) in Accounts Payable, Total
Accounts payable
Increase (Decrease) in Accounts Payable
Schedule of Long-Term Debt Instruments [Table Text Block]
Summary of Obligations Under the Term Loan Facility
Entity Current Reporting Status
Entity Current Reporting Status
US Government Agencies Debt Securities [Member]
US Government Agencies Debt Securities [Member]
Operating expenses:
Operating Expenses [Abstract]
Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, shares authorized
Common Stock, Shares Authorized
Bitopertin [Member]
Bitopertin
Bitopertin [Member]
Product and Service
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Interest Rate
Debt Instrument, Interest Rate, Stated Percentage
Entity Shell Company
Entity Shell Company
Accrued other
Other Accrued Liabilities, Current
Cash and cash equivalents for operations
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalent
Schedule of Maturities of Long-Term Debt [Table Text Block]
Scheduled Annual Principal Payments for Term Loan
Common Stock, Shares, Issued, Total
Common stock, shares issued
Common Stock, Shares, Issued
Common stock shares issued
Statement [Table]
Statement [Table]
January Two Thousand and Twenty Five Underwritten Offering [Member]
January two thousand and twenty five underwritten offering.
January Two Thousand and Twenty Five Underwritten Offering [Member]
Jean Franchi [Member]
Jean Franchi.
Jean Franchi [Member]
Statement [Line Items]
Statement [Line Items]
Sales-based [Member]
Sales-based.
Sales-based [Member]
License agreement.
License Agreement [Member]
License Agreement [Member]
Entity Filer Category
Entity Filer Category
Liabilities and Equity
Total liabilities and stockholders' equity
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Payments to Acquire Marketable Securities
Purchases of marketable securities
Long-Term Debt, Maturity, Year Three
2029
Development [Member]
Development [Member]
Development.
Prepayment charge, percentage
Loan Prepayment Charge Percentage
Loan prepayment charge, percentage.
Cash and Cash Equivalents, Fair Value Disclosure
Cash equivalents
Other Noncash Income (Expense)
Other Noncash Income (Expense), Total
Other non-cash items
Other non-cash items
Options to Purchase Common Stock [Member]
June Two Thousand and Twenty Four Underwritten Offering [Member]
June two thousand and twenty four underwritten offering.
June Two Thousand and Twenty Four Underwritten Offering [Member]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash
Schedule of Cash and Cash Equivalents [Table Text Block]
Accrued end of term fee
Accrued End of Term Fee
Accrued end of term fee.
Noncash lease expense.
Noncash Lease Expense
Non-cash lease expense
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Summary of Computation of Basic and Diluted Net Loss Per Share
Investments Classified by Contractual Maturity Date [Table Text Block]
Schedule of Contractual Maturity
Earnings Per Share, Basic, Total
Earnings Per Share, Basic
Net loss per share, basic
License and stock purchase agreement.
License and Stock Purchase Agreement [Member]
License and Stock Purchase Agreement [Member]
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Total current liabilities
Liabilities, Current
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operations:
Mabwell Therapeutics, Inc.
Mabwell [Member]
Mabwell
Mabwell Therapeutics Inc [Member]
Stockholders' equity:
Equity, Attributable to Parent [Abstract]
Final End of Term Charge
Final end of term charge.
Final end of term charge
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit)
Sale of Stock, Price Per Share
Sale of common stock, price per share
Accrued External Research And Development Expenses Current
The amount of accrued external research and development expenses current.
Accrued external research and development expenses
Equity incentive plans
Share-Based Payment Arrangement [Text Block]
Stock-Based Compensation
Debt Instrument Covenant Minimum Credit Outstanding
Debt instrument covenant minimum credit outstanding.
Aggregate minimum principal amount
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Amendment Flag
Amendment Flag
Product and Service
Product and Service [Domain]
Purchase of common stock for pre-funded warrants, shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
CommonStockSharesOutstanding
Liabilities and Equity [Abstract]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock [Member]
Common Stock [Member]
Long-Term Debt, Maturity, Year One
2027
Debt Securities, Available-for-Sale [Line Items]
Entity Address, Address Line One
Entity Address, Address Line One
DISC Three Four Zero Five [Member]
DISC three four zero five.
DISC-3405 [Member]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Supplemental cash flow information
Supplemental Cash Flow Information [Abstract]
Prepayment Charge, Percentage After Eighteen Months
Loan Prepayment Charge Percentage After Eighteen Months
Loan prepayment charge percentage after eighteen months.
Operating Lease, Right-of-Use Asset
Operating right-of-use assets
Operating right-of-use assets
Right-of-use assets, operating leases
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Unrealized loss on marketable securities
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Line Of Credit Facility [Table]
Line of Credit Facility [Table]
Upfront non-refundable payment.
Upfront Non-refundable Payment
Non-refundable upfront payment
Prime Rate [Member]
Prime Rate [Member]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase (decrease) in cash, cash equivalents and restricted cash
Sale of pre-funded warrant, price per warrant
Pre-funded warrant, price per warrant.
Sale of pre-funded warrant, price per warrant
Antidilutive securities
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Non Cash Interest Expense
Non cash interest expense.
Non-cash interest expense
Common stock, par value (in Dollars per share)
Common Stock, Par or Stated Value Per Share
Common stock share exchange value
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Total other comprehensive income
Total other comprehensive loss
Future milestone payment.
Future Milestone Payment
Future milestone payment
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost, Total
Amortized Cost
Stock Issued During Period Shares Restricted Stock Units Vested
Stock issued during period shares restricted stock units vested.
Issuance of common stock upon vesting of restricted stock units (in shares)
Debt Securities, Available-for-Sale
Total available-for-sale securities
Estimated Fair Value
Marketable securities
Common Stock in Underwritten Offering, Issuance Costs
Common stock in underwritten offering issuance costs.
Common stock in underwritten offering, issuance costs
Pre-funded warrants outstanding
Pre-funded Warrants Outstanding
Pre-funded warrants outstanding.
Debt Instruments [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Issuance of common stock upon exercise of stock options (in Shares)
Exercised
Debt Disclosure [Abstract]
State income tax expense
State and Local Income Tax Expense (Benefit), Continuing Operations
State and Local Income Tax Expense (Benefit), Continuing Operations, Total
Accrued Liabilities, Current
Accrued expenses
Other accrued expenses
Total other accrued expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Debt Instrument [Table]
Schedule of Long-Term Debt Instruments [Table]
Term loan exit fee rate
End of Term Charge Rate
End of Term Charge Rate
Document Quarterly Report
Document Quarterly Report
Entity Address, State or Province
Entity Address, State or Province
Increase (Decrease) in Other Accrued Liabilities
Other accrued expenses
Debt Issuance Costs, Gross
Unamortized deferred financing costs
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding
Preferred stock outstanding
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Line of Credit Facility, Lender
Line of Credit Facility, Lender [Domain]
Marketable Securities, Current
Marketable securities
Offering expenses.
Offering Expenses
Offering expenses
Summary of Stock-based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Issuance of common stock upon exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Other Research [Member]
Other Research [Member]
Other research.
Collaborative Arrangement Disclosure [Text Block]
Licensing Activities and Business Development
Long-Term Debt, Maturity, Remainder of Fiscal Year
Remainder of 2026
Other Assets, Noncurrent, Total
Other assets
Other Assets, Noncurrent
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Unamortized debt discount and issuance costs
Debt discount and debt issuance costs
Antidilutive Securities
Antidilutive Securities [Axis]
Interest Expense, Debt, Total
Interest expense
Interest Expense, Debt
Proceeds from Sale of Pre Funded Warrants in Underwritten Offerings, Net of Issuance Costs Paid
Proceeds from sale of pre-funded warrants in underwritten offerings, net of issuance costs paid
Proceeds from sale of pre-funded warrants in underwritten offering, net of issuance costs paid
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Significant Segment Expense Category [Member]
Significant Segment Expense Category [Member]
Significant segment expense category.
Cash and Cash Equivalents
Cash and Cash Equivalents [Domain]
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2025 and December 31, 2024
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026 and December 31, 2025
Selling, General and Administrative Expense
Selling, General and Administrative Expense, Total
Selling, general and administrative
Selling, general and administrative expense
Selling, general and administrative expense
Maturity Date
Debt Instrument, Maturity Date
Minimum [Member]
Minimum [Member]
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Segment Reporting [Abstract]
Current liabilities:
Liabilities, Current [Abstract]
Segment Reporting, Other Segment Item, Composition, Description
Future Consideration Recievable on Clinical
Future consideration recievable on clinical.
Future consideration recievable on clinical
Related Party Transactions [Abstract]
Debtor Reorganization Items, Impairment Loss
Charges for credit-related impairments
Balance (in Shares)
Balance (in Shares)
Shares, Outstanding
Proceeds from Stock Plans
Contributions from employee stock purchase plan
Commitments and Contingencies
Commitments and contingencies (Note 14)
Stock-based compensation expense (in Shares)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total
Proceeds from sale of common stock
Net Proceeds From Issuance Of Common Stock and Pre Funded Warrants
Net proceeds from issuance of common stock and pre funded warrants.
Accrued Liabilities [Abstract]
Long-Term Debt, Maturity, Year Two
2028
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Weighted-average common shares outstanding-basic
Hercules Loan Agreement [Member]
Hercules Loan Agreement [Member]
Hercules loan agreement.
Segments [Axis]
Long-Term Debt
Principal amount
Long-term debt, net
Long-term debt, net
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Future Consideration Recievable on Regulatory
Future consideration recievable on regulatory.
Future consideration recievable on regulatory
Variable Rate
Variable Rate [Domain]
Total stockholders' equity
Balance
Balance
Equity, Attributable to Parent
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in Dollars per share)
Preferred stock, par value (in Dollars per share)
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
Statement of Stockholders' Equity [Abstract]
Selcodebart [Member]
Selcodebart.
Selcodebart [Member]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Schedule of Accrued Liabilities [Table Text Block]
Summary of Other Accrued Expenses
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Other segment items
Segment Reporting, Other Segment Item, Amount
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Credit Facility
Credit Facility [Axis]
Related Party
Related and Nonrelated Parties [Axis]
February Two Thousand And Twenty Three Underwritten Offering [Member]
February two thousand and twenty three underwritten offering.
February Two Thousand And Twenty Three Underwritten Offering [Member]
Oak Bay Biosciences, Inc [Member]
Oak Bay Biosciences, Inc.
OBB [Member]
Entity Address, City or Town
Entity Address, City or Town
Number of reportable segments
Number of Reportable Segments
Security Exchange Name
Security Exchange Name
Credit Facility
Credit Facility [Domain]
Term Loan [Member]
Term loan.
Term Loan [Member]
Long-Term Debt, Gross
Total
Principal term loan balance
Loss before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Tranche One A [Member]
Tranche One A [Member]
Tranche One A.
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Stockholders' Equity Note [Abstract]
Future Milestone Recievable
Future milestone recievable.
Future milestone recievable
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash, cash equivalents and restricted cash, end of period
Cash, cash equivalents and restricted cash, beginning of period
Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows
Interest Paid, Excluding Capitalized Interest, Operating Activity
Cash paid for interest
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statistical Measurement
Statistical Measurement [Domain]
Total current assets
Assets, Current
Stock-based compensation expense
Share-based Payment Arrangement, Expense
Share-Based Payment Arrangement, Expense
Stock-based compensation expense
Document Period End Date
Document Period End Date
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Long-Term Debt [Text Block]
Long-Term Debt
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Restricted stock units [Member]
Roche
Roche [Member]
Roche [Member]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Other comprehensive loss:
Number of investments
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Total liabilities
Liabilities
Non refundable upfront fee.
Non Refundable Upfront Fee
Non refundable upfront fee
Financial Instruments [Domain]
Restricted Cash
Restricted Cash, Total
Restricted cash
Variable Rate
Variable Rate [Axis]
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average common shares outstanding-diluted
Entity File Number
Securities Act File Number
Cover [Abstract]
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Cash and Cash Equivalents Disclosure [Text Block]
Cash, Cash Equivalents and Restricted Cash
October Two Thousand and Twenty Five Underwritten Offering [Member]
October two thousand and twenty five underwritten offering.
October Two Thousand and Twenty Five Underwritten Offering [Member]
US Treasury Securities [Member]
US Treasury Securities [Member]
Number of Operating Segments
Number of operating segments
Sale of Stock [Domain]
Segment Reporting Disclosure [Text Block]
Segment Information
General and Administrative Expense
General and administrative expense
Development and Regulatory Milestone First Indication [Member]
Development and regulatory milestone first indication.
Development and Regulatory Milestone First Indication [Member]
Marketable Securities [Abstract]
Recently Adopted and Issued Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Upfront cash payment
Upfront Cash Payment
Upfront cash payment.
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Variable Interest Entity, Initial Consolidation, Gain (Loss)
Loss from initial consolidation of variable interest entity
Tranche Four [Member]
Tranche four.
Tranche Four [Member]
Proceeds from Issuance of Long-Term Debt
Proceeds from Issuance of Long-Term Debt, Total
Proceeds from long-term debt, net of issuance costs paid
Milestone Payments
Milestone payments.
Milestone payments
Prepayment Charge, Percentage Thereafter
Loan Prepayment Charge Percentage Thereafter
Loan prepayment charge percentage thereafter.
Common stock, shares outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding
Sale of common stock
Operating Lease, Liability, Current
Operating lease liabilities, current
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Depreciation, Depletion and Amortization, Total
Depreciation, Depletion and Amortization
Depreciation and amortization
Stock Issued During Period Value Sale of Common Stock in Underwritten Offering
Stock issued during period value sale of common stock in underwritten. Offering
Sale of common stock in underwritten offering
Commercial Expense
Commercial expense.
Commercial expense
Document Transition Report
Document Transition Report
Total operating expenses
Operating Expenses
Research and Development Expense, Total
Research and development expense
Research and Development Expense
Research and development personnel-related expense
Research and development
Research and development expense
Asset impairment charges
Asset Impairment Charges
Asset Impairment Charges, Total
Statement of Cash Flows [Abstract]
Stock Issued During Period Value Sale of Pre Funded Warrants in Underwritten Offering
Stock issued during period value sale of pre funded warrants in underwritten offering.
Sale of pre-funded warrants in underwritten offering
Equity [Text Block]
Stockholders' Equity
Net Loss Per Share
Earnings Per Share [Text Block]
Issuance of share (in Shares)
Shares, Issued, Beginning Balance
Shares, Issued, Ending Balance
Shares, Issued
Number of shares issued
Floating Annual Rate [Member]
Floating annual rate
Net loss
Net loss
Net loss
Non Rule 10B51 Arr Modified Flag
Non rule10b51 arrangement modified flag.
Non-Rule 10b5-1 Arrangement Modified
Other Segment Items [Member]
Other segment items.
Other Segment Items [Member]
Line Of Credit Facility [Line Items]
Line of Credit Facility [Line Items]
Assets
Assets [Abstract]
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Increase (Decrease) in Prepaid Expense and Other Assets
Document Fiscal Year Focus
Document Fiscal Year Focus
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Cash flows from investing activities:
Cash flows from investing activities
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Interest Expense, Nonoperating
Interest Expense, Nonoperating, Total
Interest expense
Interest expense
Research and Development Expense [Member]
Research and Development
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Marketable Securities
Development and Regulatory First Indication Second Milestone [Member]
Development and regulatory first indication second milestone.
Development and Regulatory First Indication Second Milestone [Member]
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period
The amount of other comprehensive income unrealized holding gain loss on securities arising during period.
Unrealized gain/loss on marketable securities
Option shares available to purchase for underwriter.
Option Shares Available To Purchase For Underwriter
Option shares available to purchase for underwriter
Pre-funded warrants in underwritten offering, issuance costs
Pre-Funded Warrants in Underwritten Offering, Issuance Costs
Pre-funded warrants in underwritten offering, issuance costs.
Proceeds from Stock Options Exercised
Proceeds from stock option exercises
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Development and Regulatory Second Indication First Milestone [Member]
Development and regulatory second indication first milestone.
Development and Regulatory Second Indication First Milestone [Member]
Purchase price
Sale of Stock, Consideration Received on Transaction
Sale of common stock
Share-Based Payment Arrangement [Abstract]
Amount of Upfront Payment Received
Amount of upfront payment received.
Upfront payment received
Assets, Fair Value Disclosure
Total assets
Total assets
Sale of Stock [Axis]
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Aggregate future offer, issuance and sale
Maximum aggregate value of future offer, issuance and sale of shares as agreed upon.
Sale of Stock Agreement, Aggregate Future Offer, Issuance and Sale
Money Market Funds [Member]
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Increase Decrease In Accrued External Research and Development Expenses
Increase decrease in accrued external research and development expenses
Accrued external research and development expenses
Development and Regulatory First Indication First Milestone [Member]
Development and Regulatory First Indication First Milestone [Member]
Development and regulatory first indication first milestone.
Merger agreement.
Merger Agreement [Member]
Merger Agreement [Member]
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Income Tax Disclosure [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Income Statement Location
Statement of Income Location, Balance [Axis]
Trading Symbol
Trading Symbol
Unaudited Interim Condensed Consolidated Financial Information
Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block]
Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block]
Development and Regulatory Milestone Second Indication [Member]
Development and regulatory milestone second indication.
Development and Regulatory Milestone Second Indication [Member]
Employee-related Liabilities, Current, Total
Employee-related Liabilities, Current
Accrued employee-related expenses
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Cash flows from financing activities:
Cash flows from financing activities:
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Other Accrued Expenses
Equity Components
Equity Components [Axis]
Nonoperating Income (Expense)
Total other income (expense), net
Equity Component
Equity Component [Domain]
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Issuance of common stock under employee stock purchase plan (in shares)
Maximum [Member]
Maximum [Member]
Maximum
Statistical Measurement
Statistical Measurement [Axis]
William Savage [Member]
William Savage.
William Savage [Member]
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued
Common stock, $0.0001 par value; 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 38,345,666 and 37,890,616 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Net proceeds, after deducting placement agent fees and offering expenses
Net Proceeds From Issuance Of Common Stock
Net proceeds from issuance of common stock.
Stock Issued During Period Sale of Common Stock in Underwritten Offering Shares
Stock issued during period sale of common stock in underwritten offering shares.
Sale of common stock in underwritten offering (in Shares)
Cash and Cash Equivalents [Abstract]
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive loss:
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Preferred stock authorized
Commercialization [Member]
Commercialization.
Commercialization [Member]
Lender Name
Lender Name [Axis]
Employee Stock [Member]
Entity Registrant Name
Entity Registrant Name
Stock Issued During Period Values Restricted Stock Units Vested
Stock issued during period values restricted stock units vested
Issuance of common stock upon vesting of restricted stock units
Tranche One B [Member]
Tranche One B.
Tranche One B [Member]
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross Unrealized Losses
Other Nonoperating Income (Expense), Total
Other Nonoperating Income (Expense)
Other (expense) income
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Ending Balance
Additional Paid in Capital
Income tax expense
Income Tax Expense (Benefit), Total
Income Tax Expense (Benefit)
Income Tax Expense (Benefit)
Proceeds from sale of common stock in registered direct offering, net of issuance costs paid
Proceeds from Issuance of Common Stock
Proceeds from sale of common stock
Business Combination, Contingent Consideration, Type [Axis]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration of Credit Risk and of Significant Suppliers
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive (loss) income
Federal income taxes
Federal Income Tax Expense (Benefit), Continuing Operations
Federal Income Tax Expense (Benefit), Continuing Operations, Total
Payments to Acquire Property, Plant, and Equipment, Total
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Total assets
Assets
Internal Research and Development [Member]
Internal research and development.
Internal Research and Development [Member]
Tranche Two and Three [Member]
Tranche two and three.
Tranche Two and Three [Member]
Income Statement [Abstract]
Selling, General and Administrative Expenses [Member]
Selling, General and Administrative
Number of shares subscribed (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Sale of common stock, shares
Aggregate fair value of marketable securities in unrealized loss
Aggregate Fair Value of Marketable Securities in unrealized Loss Position
Aggregate fair value of marketable securities in unrealized loss position.
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Net loss per share, diluted
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Significant Segment Expense Categories
City Area Code
City Area Code
June Two Thousand and Twenty Three Underwritten Offering [Member]
June Two Thousand And Twenty Three Underwritten Offering [Member]
June Two Thousand And Twenty Three Underwritten Offering [Member]
Debt Instrument, Face Amount
Additional principle amount
Debt instrument face amount
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies [Policy Text Block]
Summary of significant accounting policies.
Stock Issued During Period, Value, Employee Stock Purchase Plan
Issuance of common stock under employee stock purchase plan
Future Consideration Recievable on Sales Milestones
Future consideration recievable on sales milestones.
Future consideration recievable on sales milestones
Segment Reporting Information [Line Items]
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net
Cantor ATM Agreement [Member]
Cantor ATM agreement.
Cantor ATM Agreement [Member]
Loss from operations
Operating Income (Loss)
Retained Earnings [Member]
Accumulated Deficit [Member]
Business Combination, Contingent Consideration, Type [Domain]
Cash and Cash Equivalents
Cash and Cash Equivalents [Axis]
Stock-based compensation
Share-based Payment Arrangement, Noncash Expense, Total
Share-Based Payment Arrangement, Noncash Expense
Operating Lease, Liability, Noncurrent
Operating lease liabilities, non-current
Operating Lease, Liability, Noncurrent, Total
Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Class of Stock [Line Items]
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Business Combination Contingent Consideration Sales Based Milestone Payments
Business combination contingent consideration sales based milestone payments.
Contingent and sales-based milestone payments
Secured Debt [Member]
Secured Debt [Member]
Nonoperating Income (Expense) [Abstract]
Other income (expense), net:
Marketable Securities [Table Text Block]
Schedule of Marketable Securities
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share
Corporate Debt Securities [Member]
Corporate Debt Securities [Member]
Proceeds from Sale of Common Stock in Underwritten Offering, Net of Issuance Costs Paid
Proceeds from sale of common stock in underwritten offerings, net of issuance costs paid.
Proceeds from sale of common stock in underwritten offering, net of issuance costs paid
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Income Statement Location
Statement of Income Location, Balance [Domain]
Cash flows from operating activities:
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture, Total
Stock-based compensation expense
Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture
Upfront payment.
Upfront Payment
Upfront payment
Accretion (Amortization) of Discounts and Premiums, Investments
Amortization/accretion of investment securities
Debt Instrument Covenant Minimum Market Capitalization
Debt instrument covenant minimum market capitalization.
Market capitalization covenant
Entity Tax Identification Number
Entity Tax Identification Number
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Maturities of marketable securities
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization and Nature of the Business
Tranche one.
Tranche One [Member]
Tranche One [Member]
Interest income
Interest Income, Other
Local Phone Number
Local Phone Number
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value
Due after one year through five years
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value
Due within one year
Rule 10B51 Arr Modified Flag
Rule10b51 arrangement modified flag.
Rule 10b5-1 Arrangement Modified
Accounting Policies [Abstract]
Key Measure of Segment Profit or Loss [Member]
Key measure of segment profit or loss.
Key Measure of Segment Profit or Loss [Member]
Accrued professional fees
Accrued Professional Fees, Current
Cash, cash equivalents and short-term marketable securities
Cash, Cash Equivalents, and Short-Term Investments
Cash, Cash Equivalents, and Short-Term Investments, Total
Stock, Class of Stock [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company